Metrics to compare | HIND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHINDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −1.7x | −0.2x | |
PEG Ratio | −0.04 | −0.04 | 0.00 | |
Price/Book | 1.9x | 1.8x | 2.6x | |
Price / LTM Sales | 66.5x | 1.7x | 2.7x | |
Upside (Analyst Target) | - | 172.0% | 72.2% | |
Fair Value Upside | Unlock | 39.5% | 12.4% | Unlock |
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.